Revvity

What Revvity does

Revvity, Inc. (NYSE: RVTY) is a life sciences and diagnostics company headquartered in Waltham, Massachusetts, formed in 2023 through the spin-off of PerkinElmer's Life Sciences and Diagnostics divisions. The company operates across two reportable segments — Life Sciences Tools and Diagnostics — serving pharmaceutical and biotechnology companies (94% of top 50 global pharma), clinical laboratories, academic institutions, contract research organizations, and healthcare professionals in more than 160 countries. Its portfolio spans reagents and consumables (BioLegend antibodies, AlphaLISA, HTRF, Dharmacon, Mimix reference standards), instruments (Opera Phenix OptIQ high-content screening, EnVision Nexus One plate readers, chemagic nucleic acid systems, IVIS in vivo imaging, Fontus/Sciclone/Zephyr workstations), diagnostics (T-SPOT.TB, Vanadis NIPT, IDS immunoassays, EUROIMMUN, ViaCord), and software (Signals One, Signals AI, Signals BioDesign, Signals Xynthetica, ChemDraw, Spotfire).

Name

Revvity

Legal name

Revvity, Inc.

Website

https://revvity.com

Company type

Public

Founded year

2023

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Revvity is a publicly traded life sciences and diagnostics company (NYSE: RVTY) that provides reagents, instruments, software, and clinical services to pharma, biotech, clinical labs, and academia across 160+ countries, with growing AI-enabled informatics via the Signals platform.

Ownership category

akta.pro rank

Product category

Life Sciences Tools and Diagnostics

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)

SIC

Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372)

akta.pro primary industry

Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)

akta.pro secondary industries

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM), Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

Keywords

• Life sciences reagents
• Clinical diagnostics
• Research informatics software
• Drug discovery tools
• In vitro diagnostics

Headquarters

HQ city

Waltham

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Life Sciences Tools and Consumables: Revenue from reagents, antibodies, assay kits, and consumables for life sciences research. Includes BioLegend reagents, AlphaLISA, HTRF, DELFIA, and Dharmacon CRISPR/RNAi products. Strong recurring revenue from consumables with consumables pull-through driving growth.
2. Instruments and Automation: Sale of instruments including microplate readers (EnVision), high-content screening systems (Opera Phenix), liquid handling workstations, and in vivo imaging systems (IVIS). Instruments often paired with reagent rental or service contracts.
3. Clinical Diagnostics: Revenue from diagnostic platforms and tests including reproductive health (newborn screening, prenatal testing), immunodiagnostics, infectious disease testing, and oncology. Includes IVD instruments and reagents for clinical laboratories.
4. Software Subscriptions (Signals Platform): SaaS and subscription revenue from Revvity Signals software including Signals One, ChemDraw, Signals Notebook, and Signals Clinical. Software integrations with AI capabilities drive recurring revenue.
5. Revvity Omics Clinical Services: Genomic testing services including whole genome sequencing, newborn screening services, rare disease testing, prenatal testing, and hereditary cancer testing through global laboratory network.
6. Technology Licensing: Licensing revenue from proprietary platforms including CHOSOURCE expression system, Pin-point base editing platform, LentiBOOST transduction technology, and viral vector technologies for gene therapy manufacturing.
7. Preclinical Services: Contract services including antibody drug conjugate services, cell line engineering, viral vector manufacturing, functional genomic screening, and base editing services for pharma and biotech clients.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

Revvity provides life sciences reagents and instruments, clinical diagnostics solutions, and AI-enabled R&D informatics software (Signals One platform) for drug discovery, translational research, and clinical diagnostics. Its portfolio spans research consumables (BioLegend antibodies, Dharmacon CRISPR/RNAi, AlphaLISA, HTRF), high-throughput screening instruments (Opera Phenix, EnVision Nexus), IVD platforms (T-SPOT.TB, Vanadis, EUROIMMUN), and proprietary cell/gene therapy platforms (CHOSOURCE, Pin-point, LentiBOOST). The company serves pharma, biotech, clinical labs, and academic customers in more than 160 countries.

Product overview

Revvity offers a comprehensive portfolio of life sciences and diagnostics solutions organized around a platform-plus-modules architecture. The core offering includes the Signals One R&D informatics platform, which integrates with specialized modules including Signals AI (agentic AI framework), Signals BioDesign (cloud-native molecular cloning), Signals Xynthetica (Models-as-a-Service for predictive modeling), Signals Clinical (clinical trial data management), Signals Notebook (ELN), ChemDraw (chemical visualization), and Spotfire (data analytics - exclusive reseller). Supporting the software platform is a broad portfolio of instruments including Opera Phenix OptIQ high-content screening systems, EnVision Nexus One plate readers, chemagic nucleic acid purification systems, IVIS in vivo imaging, Fontus automated workstations, and Omni homogenizers. The reagent portfolio includes BioLegend antibodies, AlphaLISA/HTRF immunoassays, Dharmacon CRISPR/RNAi tools, and Mimix reference standards for diagnostics. Diagnostics offerings include T-SPOT.TB tuberculosis testing, Vanadis cell-free DNA platforms, IDS immunoassay systems, EUROIMMUN autoimmune/infectious disease tests, and ViaCord cord blood banking. Licensing technologies include CHOSOURCE expression platform and Pin-point base editing platform. The company also provides clinical genomics services through Revvity Omics including newborn screening, rare disease testing, and whole genome sequencing.

Differentiator

Problem solved

Functional benefit

Brands

• BioLegend: Antibodies and reagents for life science research
• Euroimmun
• Revvity Omics
• Revvity Signals
• Tulip Diagnostics
• ViaCord
• Immunodiagnostic Systems (IDS)
• Opera Phenix
• EnVision
• IVIS
• T-SPOT
• AlphaLISA
• HTRF
• chemagic
• CHOSOURCE
• Pin-point
• LentiBOOST

Products and services

• Signals One Platform

Quantifiable outcome

• 94% of top 50 pharmaceutical companies worldwide use Revvity solutions
• +6 more outcomes

Named customers9 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration8 records

AI capability11 records

Feature13 records

Partnerships

Eight partnerships are on record, tiered core and flagship.

• AnthropiccoreTechnology or Integration · 1 July 2026Revvity Signals Software joined Anthropic's Model Context Protocol (MCP) directory, enabling scientists to access Signals AI capabilities through Claude. The integration allows researchers to securely access experimental data, organizational knowledge, and scientific context through natural language interactions while maintaining traceability. Extends Signals AI beyond Signals One platform.
• New England Biolabs (NEB)coreTechnology or Integration · 6 February 2026Collaboration for automating NEBNext reagents for next-generation sequencing library preparation on automated workstations. Includes Hamilton Company, Revvity, SPT Labtech, and Beckman Coulter. Standardized, automation-ready workflows reduce implementation time and validation burden for laboratories.
• Eli Lilly and CompanyflagshipStrategic or Co-development Partner · 12 January 2026Collaboration to make Lilly's TuneLab predictive AI models available through Revvity's Signals Xynthetica platform. Uses federated learning to enable biotech access to AI models while maintaining data confidentiality. Both companies jointly fund access for small- and mid-sized biotechs. Followed by 2.7% stock rise.
• ACD/LabscoreTechnology or Integration · 10 November 2025Revvity announced acquisition of ACD/Labs to expand Signals software capabilities and research informatics offerings. The acquisition enhances Revvity's analytical and molecular design tools integration into the Signals platform for pharmaceutical and material sciences workflows. Transaction expected to close late Q4 2025.
• MDIC and NISTcoreStrategic or Co-development Partner · 10 November 2025Launch of new somatic cancer reference standards (Mimix Geni) developed with MDIC and NIST for use in developing and validating NGS-based cancer diagnostics. Contains seven oncogenic mutations validated for assay sensitivity, specificity, and reproducibility.
• Bionano GenomicscoreTechnology or Integration · 1 June 2024Partnership between Bionano Genomics and Revvity for optical genome mapping solutions. Bionano launched OGM Dx Postnatal Whole Genome SV test and partnered with Revvity in June 2024 for market expansion.
• ProfluentcoreStrategic or Co-development PartnerPartnership to integrate AI-designed enzymes into Revvity's base editing platforms. Profluent raised $106M Series funding led by Jeff Bezos's Bezos Expeditions. Enables design of novel enzymes not found in nature to expand therapeutic possibilities.
• ISN MedicalcoreStrategic or Co-development PartnerPartnership with ISN Medical in Nigeria to support newborn screening campaign to screen one million newborns for congenital and inherited conditions from 2026 to 2030. Initiative supported by Federal Ministry of Health and Social Welfare through Health Sector Reform Agenda.

Scale indicators14 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Sartorius: Bioprocessing and lab essentials competitor identified alongside Revvity in the viral capsid/cell and gene therapy manufacturing market.
• Thermo Fisher Scientific: Largest life sciences tools and diagnostics company with comparable instruments, reagents, software, and clinical diagnostics portfolios serving pharma, biotech, and academic customers globally.
• Danaher Corporation: Diversified life sciences and diagnostics conglomerate spanning bioprocessing (Cytiva), life sciences instruments (Beckman Coulter), and clinical diagnostics (Beckman, Leica, Radiometer) with overlapping customer base.
• Mettler-Toledo International: Laboratory and industrial instruments peer with comparable precision measurement, automation, and pharma/biotech customer base.
• PerkinElmer: Revvity's former parent; retains applied services and informatics segments post spin-off, providing partial product overlap in life sciences and diagnostics.

Direct peers

• QIAGEN: Direct peer in molecular diagnostics, sample technologies, and life sciences reagents with comparable genomic analysis, infectious disease, and pharma/biotech offerings.
• Illumina: Genomic sequencing and array platform peer serving overlapping pharma/biotech and clinical diagnostics customers in reproductive health, oncology, and rare disease.
• Agilent Technologies: Direct competitor in analytical instruments, genomics, and cell analysis with comparable microplate readers, reagent kits, and biopharma customer base.
• Bio-Rad Laboratories: Competes head-to-head in life science research reagents, clinical diagnostics, and digital PCR/qPCR instruments, with similar mid-cap scale and biopharma exposure.
• Waters Corporation: Specialty analytical instruments and informatics competitor; identified alongside Revvity as a defensive healthcare equipment pick by T. Rowe Price.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/RevvityInc
• YouTubeyoutube.com/channel/UCUqLrqOpUUwhz3UaLn78tVQ
• Facebookfacebook.com/RevvityInc
• LinkedInlinkedin.com/company/revvity
• Instagraminstagram.com/revvity

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries7 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Revvity